Novo Still Has Work to Do to Build Investor Confidence, CEO Says
Why now
Thesis: CEO comments signal competitive pressure and need to rebuild trust.
Catalyst to watch: Obesity pipeline updates and investor confidence efforts.
Main risk: Competitive pressure and weak investor confidence.
Why it matters
CEO comments on obesity pipeline signal competitive pressure and need to rebuild investor trust.
Details
Novo CEO Mike Doustdar discusses investor confidence, drug testing and the potential for expanding the firm's obesity offerings. "We should also have a mindset that we don't have a patent or a monopoly on all the good ideas," Doustdar tells Bloomberg Television. "When there is a gap, strategically o
Sources
- youtube · 2026-09-22 07:12 UTC